标题
Current Development Status of MEK Inhibitors
作者
关键词
-
出版物
MOLECULES
Volume 22, Issue 10, Pages 1551
出版商
MDPI AG
发表日期
2017-09-27
DOI
10.3390/molecules22101551
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- MEK inhibitors in oncology: a patent review (2015-Present)
- (2017) Debarshi Kar Mahapatra et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer
- (2017) Pasi A. Jänne et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A phase IB study of the combination of selumetinib (AZD6244; ARRY-142886) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer (mCRC).
- (2017) Anuradha Krishnamurthy et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non–Small Cell Lung Cancer
- (2017) David R. Gandara et al. Journal of Thoracic Oncology
- Binimetinib versus dacarbazine in patients with advanced NRAS -mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
- (2017) Reinhard Dummer et al. LANCET ONCOLOGY
- LGG-08. A PHASE II PROSPECTIVE STUDY OF SELUMETINIB IN CHILDREN WITH RECURRENT OR REFRACTORY LOW-GRADE GLIOMA (LGG): A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY
- (2017) Jason Fangusaro et al. NEURO-ONCOLOGY
- A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study
- (2017) Anuradha Banerjee et al. NEURO-ONCOLOGY
- A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)
- (2016) W. M. Tai et al. ANNALS OF ONCOLOGY
- A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours
- (2016) David Jamieson et al. EUROPEAN JOURNAL OF CANCER
- A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors
- (2016) Alex A. Adjei et al. INVESTIGATIONAL NEW DRUGS
- A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors
- (2016) Lee S. Rosen et al. INVESTIGATIONAL NEW DRUGS
- Functional and genetic screening of acute myeloid leukemia associated with mediastinal germ cell tumor identifies MEK inhibitor as an active clinical agent
- (2016) Jessica T. Leonard et al. Journal of Hematology & Oncology
- Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
- (2016) Weijie Ma et al. Journal of Hematology & Oncology
- Emerging therapeutic agents for lung cancer
- (2016) Bhagirathbhai Dholaria et al. Journal of Hematology & Oncology
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- Dabrafenib plus trametinib in patients with previously treated BRAF V600E -mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
- (2016) David Planchard et al. LANCET ONCOLOGY
- Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer
- (2016) Jean-Luc Van Laethem et al. Targeted Oncology
- Absorption, metabolism and excretion of cobimetinib, an oral MEK inhibitor, in rats and dogs
- (2016) Ryan H. Takahashi et al. XENOBIOTICA
- Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma
- (2015) Paola Queirolo et al. CANCER TREATMENT REVIEWS
- MEK inhibitors beyond monotherapy: current and future development
- (2015) Ian E Templeton et al. CURRENT OPINION IN PHARMACOLOGY
- BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma
- (2015) Juliet Richman et al. EXPERT OPINION ON PHARMACOTHERAPY
- Nivolumab plus ipilimumab in the treatment of advanced melanoma
- (2015) Katy K. Tsai et al. Journal of Hematology & Oncology
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- (2015) Georgina V Long et al. LANCET
- A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma
- (2014) H. Y. Lim et al. CLINICAL CANCER RESEARCH
- Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma
- (2014) A. M. Menzies et al. CLINICAL CANCER RESEARCH
- Prospects for MEK inhibitors for treating cancer
- (2014) Juan Martin-Liberal et al. Expert Opinion On Drug Safety
- Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in vitro
- (2013) Emanuel Haasbach et al. ANTIVIRAL RESEARCH
- Modulation of endochondral ossification by MEK inhibitors PD0325901 and AZD6244 (Selumetinib)
- (2013) J. El-Hoss et al. BONE
- Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI
- (2013) M Beloueche-Babari et al. BRITISH JOURNAL OF CANCER
- CInQ-03, a novel allosteric MEK inhibitor, suppresses cancer growth in vitro and in vivo
- (2013) Dong Joon Kim et al. CARCINOGENESIS
- Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial
- (2013) N. Jain et al. CLINICAL CANCER RESEARCH
- A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies
- (2013) Roger B. Cohen et al. EUROPEAN JOURNAL OF CANCER
- MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
- (2013) Paolo A Ascierto et al. LANCET ONCOLOGY
- Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers
- (2013) Georgia Hatzivassiliou et al. NATURE
- BRAF inhibitors in cancer therapy
- (2013) Carolina Hertzman Johansson et al. PHARMACOLOGY & THERAPEUTICS
- MEK in cancer and cancer therapy
- (2013) Cindy Neuzillet et al. PHARMACOLOGY & THERAPEUTICS
- PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts
- (2012) Edna F. Choo et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors
- (2012) S. Leijen et al. CLINICAL CANCER RESEARCH
- First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors
- (2012) M. Martinez-Garcia et al. CLINICAL CANCER RESEARCH
- 502 Preclinical Pharmacokinetics and Efficacy Assessment of a Potent and Selective MEK Inhibitor, GDC-0623
- (2012) E. Choo et al. EUROPEAN JOURNAL OF CANCER
- 608 Phase I Dose-escalation Trial of a Selective Oral MEK1/2 Inhibitor, Pimasertib (MSC1936369B), Combined with an mTOR Inhibitor, Temsirolimus, in Patients with Advanced Solid Tumors
- (2012) A. Naing et al. EUROPEAN JOURNAL OF CANCER
- 616 Pimasertib (MSC1936369B/AS703026), a Selective Oral MEK1/2 Inhibitor, Shows Clinical Activity in Melanoma
- (2012) J.P. Delord et al. EUROPEAN JOURNAL OF CANCER
- 604 Safety and Recommended Phase II Dose (RP2D) of the Selective Oral MEK1/2 Inhibitor Pimasertib (MSC1936369B/AS703026): Results of a Phase I Trial
- (2012) A. Awada et al. EUROPEAN JOURNAL OF CANCER
- 600 Pharmacokinetics and Pharmacodynamics of a Selective Oral MEK1/2 Inhibitor, Pimasertib (MSC1936369B/AS703026), in Patients with Advanced Solid Tumors
- (2012) N. Houédé et al. EUROPEAN JOURNAL OF CANCER
- Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines
- (2012) Brigette B. Y. Ma et al. INVESTIGATIONAL NEW DRUGS
- Differences in the Biologic Activity of 2 Novel MEK Inhibitors Revealed by 18F-FDG PET: Analysis of Imaging Data from 2 Phase I Trials
- (2012) F. Kraeber-Bodere et al. JOURNAL OF NUCLEAR MEDICINE
- Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
- (2012) Jeffrey R Infante et al. LANCET ONCOLOGY
- Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973)
- (2012) Kenneth D. Rice et al. ACS Medicinal Chemistry Letters
- Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer
- (2011) Qing Dong et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent
- (2011) Yoshiaki Isshiki et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer
- (2011) Peter D. Boasberg et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
- (2011) A. G. Gilmartin et al. CLINICAL CANCER RESEARCH
- Mitogen-activated protein kinase in the amygdala plays a critical role in lithium chloride-induced taste aversion learning
- (2011) Bumsup Kwon et al. NEUROBIOLOGY OF LEARNING AND MEMORY
- Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate)
- (2011) Hiroyuki Abe et al. ACS Medicinal Chemistry Letters
- Targeting the MAPK pathway in melanoma: Why some approaches succeed and other fail
- (2010) Gajanan S. Inamdar et al. BIOCHEMICAL PHARMACOLOGY
- A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
- (2010) E. B. Haura et al. CLINICAL CANCER RESEARCH
- Emerging MEK inhibitors
- (2010) James A McCubrey et al. EXPERT OPINION ON EMERGING DRUGS
- The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of RO5068760, an MEK Inhibitor, in Healthy Volunteers: Assessment of Target Suppression
- (2010) Lucy Lee et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Preclinical In vivo Evaluation of Efficacy, Pharmacokinetics, and Pharmacodynamics of a Novel MEK1/2 Kinase Inhibitor RO5068760 in Multiple Tumor Models
- (2010) S. Daouti et al. MOLECULAR CANCER THERAPEUTICS
- Preclinical disposition and pharmacokinetics-pharmacodynamic modeling of biomarker response and tumour growth inhibition in xenograft mouse models of G-573, a MEK inhibitor
- (2010) Edna F. Choo et al. XENOBIOTICA
- RDEA119/BAY 869766: A Potent, Selective, Allosteric Inhibitor of MEK1/2 for the Treatment of Cancer
- (2009) C. Iverson et al. CANCER RESEARCH
- AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC)
- (2009) Hung Huynh et al. JOURNAL OF HEPATOLOGY
- PD98059, a specific MAP kinase inhibitor, attenuates multiple organ dysfunction syndrome/failure (MODS) induced by zymosan in mice
- (2009) Rosanna Di Paola et al. PHARMACOLOGICAL RESEARCH
- The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901
- (2008) Stephen D. Barrett et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Putative allosteric MEK1 and MEK2 inhibitors
- (2008) Steve Price EXPERT OPINION ON THERAPEUTIC PATENTS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now